Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASNDNASDAQ:CGONNASDAQ:LEGNNASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$151.43-2.8%$145.13$111.09▼$169.37$9.19B0.62467,387 shs655,858 shsCGONCG Oncology$22.05-10.0%$27.66$21.93▼$46.99$1.68B1.6656,677 shs1.24 million shsLEGNLegend Biotech$31.52-7.1%$36.40$30.17▼$60.87$5.79B0.191.20 million shs2.20 million shsROIVRoivant Sciences$9.85-2.4%$10.69$9.76▼$13.06$7.03B1.265.40 million shs8.94 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-2.84%-5.97%-3.29%+9.99%-0.36%CGONCG Oncology-9.96%-19.93%-14.73%-23.12%-48.43%LEGNLegend Biotech-7.10%-10.07%-9.97%-3.13%-44.91%ROIVRoivant Sciences-2.38%-7.69%-8.29%-16.74%-5.56%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S3.1021 of 5 stars4.51.00.00.03.51.70.6CGONCG Oncology1.1422 of 5 stars3.60.00.00.01.90.80.0LEGNLegend Biotech2.6763 of 5 stars3.53.00.00.03.01.70.6ROIVRoivant Sciences2.4055 of 5 stars3.51.00.00.03.53.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 2.93Moderate Buy$204.6435.14% UpsideCGONCG Oncology 3.10Buy$63.88189.68% UpsideLEGNLegend Biotech 2.92Moderate Buy$79.00150.63% UpsideROIVRoivant Sciences 3.00Buy$17.1073.60% UpsideCurrent Analyst Ratings BreakdownLatest CGON, LEGN, ASND, and ROIV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025CGONCG OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.003/25/2025CGONCG OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.003/18/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$168.00 ➝ $200.003/17/2025LEGNLegend BiotechMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$82.00 ➝ $80.003/12/2025LEGNLegend BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/12/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$73.00 ➝ $75.003/7/2025CGONCG OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$55.00 ➝ $55.003/4/2025ROIVRoivant SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/25/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$170.00 ➝ $200.002/18/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$180.002/18/2025ASNDAscendis Pharma A/SEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$220.00 ➝ $260.00(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$363.64M25.27N/AN/A($1.88) per share-80.55CGONCG Oncology$684K2,451.23N/AN/A($1.94) per share-11.37LEGNLegend Biotech$627.24M9.23N/AN/A$6.88 per share4.58ROIVRoivant Sciences$122.59M57.34N/AN/A$7.76 per share1.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$7.10N/A630.96N/A-104.54%N/A-39.23%5/1/2025 (Estimated)CGONCG Oncology-$48.61M-$1.42N/AN/AN/A-10,642.98%-18.97%-15.36%N/ALEGNLegend Biotech-$518.25M-$0.48N/AN/AN/A-66.92%-29.69%-19.45%5/12/2025 (Estimated)ROIVRoivant Sciences$4.35B-$0.15N/AN/AN/A-119.54%-14.05%-12.81%5/29/2025 (Estimated)Latest CGON, LEGN, ASND, and ROIV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/25/2025Q4 2024CGONCG Oncology-$0.37-$0.48-$0.11-$0.48$0.11 million$0.46 million3/11/2025Q4 2024LEGNLegend Biotech-$0.39$0.07+$0.46$0.07$179.00 million$186.50 million2/12/2025Q4 2024ASNDAscendis Pharma A/S-$1.32-$0.68+$0.64-$0.68$115.06 millionN/A2/10/2025Q3 2025ROIVRoivant Sciences-$0.24-$0.20+$0.04$0.23$4.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ACGONCG OncologyN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.170.84CGONCG OncologyN/A35.3235.32LEGNLegend Biotech0.274.984.90ROIVRoivant SciencesN/A37.9137.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ACGONCG Oncology26.56%LEGNLegend Biotech70.89%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%CGONCG OncologyN/ALEGNLegend Biotech0.02%ROIVRoivant Sciences7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01760.69 million36.41 millionOptionableCGONCG Oncology6176.04 millionN/AOptionableLEGNLegend Biotech1,070183.65 million182.60 millionOptionableROIVRoivant Sciences860713.55 million657.18 millionOptionableCGON, LEGN, ASND, and ROIV HeadlinesRecent News About These CompaniesRoivant Sciences (NASDAQ:ROIV) Sets New 1-Year Low - Should You Sell?April 1 at 12:45 PM | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Holdings Decreased by Corebridge Financial Inc.March 31 at 4:02 AM | marketbeat.comPertento Partners LLP Acquires 646,865 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)March 30 at 7:25 AM | marketbeat.comIs the Biotech Sector Oversaturated?March 30 at 1:23 AM | uk.finance.yahoo.comLoomis Sayles & Co. L P Trims Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)March 29, 2025 | marketbeat.comNatixis Advisors LLC Has $611,000 Position in Roivant Sciences Ltd. (NASDAQ:ROIV)March 27, 2025 | marketbeat.comEric Venker, président de Roivant Sciences, vend des actions d’une valeur de 8,19 millionsMarch 26, 2025 | fr.investing.comUn initié de Roivant Sciences a vendu des actions d'une valeur de 8 190 725 dollars, selon un récent dépôt auprès de la SEC.March 26, 2025 | zonebourse.comEFG Asset Management North America Corp. Has $3.82 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)March 26, 2025 | marketbeat.comEntryPoint Capital LLC Acquires 40,964 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)March 26, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $3,489,673.32 in StockMarch 25, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 434,478 SharesMarch 25, 2025 | marketbeat.comIs Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn?March 25, 2025 | insidermonkey.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 315,522 Shares of StockMarch 25, 2025 | insidertrades.comRoivant Sciences finalizes consulting agreement with former officerMarch 22, 2025 | investing.comRoivant Sciences Ltd. (NASDAQ:ROIV) Holdings Lessened by Corbin Capital Partners L.P.March 22, 2025 | marketbeat.comRoivant Sciences finalise un accord de conseil avec une ancienne dirigeanteMarch 21, 2025 | fr.investing.comRoivant Sciences (NASDAQ:ROIV) Trading Up 5% - Here's WhyMarch 20, 2025 | marketbeat.comEn garde, Vyvgart: Immunovant rolls out MG dataMarch 20, 2025 | bioworld.comPrivium Fund Management B.V. Cuts Position in Roivant Sciences Ltd. (NASDAQ:ROIV)March 20, 2025 | marketbeat.comRoivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.March 19, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGON, LEGN, ASND, and ROIV Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$151.43 -4.43 (-2.84%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$153.10 +1.67 (+1.10%) As of 04/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.CG Oncology NASDAQ:CGON$22.05 -2.44 (-9.96%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$22.05 0.00 (0.00%) As of 04/1/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Legend Biotech NASDAQ:LEGN$31.52 -2.41 (-7.10%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$32.22 +0.70 (+2.20%) As of 04/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Roivant Sciences NASDAQ:ROIV$9.85 -0.24 (-2.38%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$9.96 +0.11 (+1.12%) As of 04/1/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
